EA031030B1 - Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение - Google Patents

Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение Download PDF

Info

Publication number
EA031030B1
EA031030B1 EA201690223A EA201690223A EA031030B1 EA 031030 B1 EA031030 B1 EA 031030B1 EA 201690223 A EA201690223 A EA 201690223A EA 201690223 A EA201690223 A EA 201690223A EA 031030 B1 EA031030 B1 EA 031030B1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
indol
methoxy
iii
piperidin
Prior art date
Application number
EA201690223A
Other languages
English (en)
Russian (ru)
Other versions
EA201690223A1 (ru
Inventor
Кристофер Адамс
Майкл Пол Каппарелли
Такеру Ехара
Раджешри Ганеш Карки
Нелло Майнольфи
Чунь ЧЖАН
Чунь Чжан
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51230246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA031030(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201690223A1 publication Critical patent/EA201690223A1/ru
Publication of EA031030B1 publication Critical patent/EA031030B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201690223A 2013-07-15 2014-07-14 Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение EA031030B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361846355P 2013-07-15 2013-07-15
US61/846,355 2013-07-15
US201461977028P 2014-04-08 2014-04-08
US61/977,028 2014-04-08
PCT/US2014/046515 WO2015009616A1 (en) 2013-07-15 2014-07-14 Piperidinyl indole derivatives and their use as complement factor b inhibitors

Publications (2)

Publication Number Publication Date
EA201690223A1 EA201690223A1 (ru) 2016-06-30
EA031030B1 true EA031030B1 (ru) 2018-11-30

Family

ID=51230246

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690223A EA031030B1 (ru) 2013-07-15 2014-07-14 Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение

Country Status (41)

Country Link
US (2) US9682968B2 (enExample)
EP (2) EP3299365A1 (enExample)
JP (1) JP6378761B2 (enExample)
KR (1) KR102242742B1 (enExample)
CN (1) CN105579444B (enExample)
AP (1) AP2016008992A0 (enExample)
AU (1) AU2014290298B2 (enExample)
BR (1) BR112016000909B1 (enExample)
CA (1) CA2917839C (enExample)
CL (1) CL2016000060A1 (enExample)
CU (1) CU24397B1 (enExample)
CY (2) CY1119767T1 (enExample)
DK (1) DK3022192T3 (enExample)
EA (1) EA031030B1 (enExample)
ES (1) ES2655855T4 (enExample)
FI (1) FIC20240032I1 (enExample)
FR (1) FR24C1036I2 (enExample)
GT (1) GT201600007A (enExample)
HR (1) HRP20172000T1 (enExample)
HU (2) HUE037510T2 (enExample)
IL (2) IL243540B (enExample)
JO (1) JO3425B1 (enExample)
LT (2) LT3022192T (enExample)
LU (1) LUC00358I2 (enExample)
MX (1) MX351291B (enExample)
MY (2) MY187454A (enExample)
NL (1) NL301292I2 (enExample)
NO (1) NO2024042I1 (enExample)
PE (1) PE20161066A1 (enExample)
PH (1) PH12016500072A1 (enExample)
PL (1) PL3022192T3 (enExample)
PT (1) PT3022192T (enExample)
RS (1) RS56721B1 (enExample)
SG (1) SG11201600086PA (enExample)
SI (1) SI3022192T1 (enExample)
SV (1) SV2016005137A (enExample)
TN (1) TN2016000017A1 (enExample)
TW (1) TWI641600B (enExample)
UA (1) UA117371C2 (enExample)
UY (1) UY35663A (enExample)
WO (1) WO2015009616A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2818684C1 (ru) * 2020-05-18 2024-05-03 Новартис Аг Кристаллическая форма lnp023

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
JP6994767B2 (ja) * 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
EP3808748B1 (en) 2016-06-21 2026-05-20 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
MX2018016046A (es) 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos medicos.
CN113444094B (zh) * 2016-07-20 2023-12-22 纳莹(上海)生物科技有限公司 一种荧光探针及其制备方法和用途
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
HRP20251596T1 (hr) * 2017-08-31 2026-01-30 Novartis Ag Nove upotrebe derivata piperidinil-indola
AU2019304216B2 (en) * 2018-07-16 2022-06-02 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives
EP3841086B1 (en) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020051538A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
US12435150B2 (en) 2019-01-11 2025-10-07 Novartis Ag Anti-CD40 antibodies for use in treatment of hidradenitis suppurativa
EP3908279B1 (en) 2019-01-11 2024-08-28 Novartis AG Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
MX2021011507A (es) 2019-03-22 2021-12-15 Achillion Pharmaceuticals Inc Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
CN120168469A (zh) * 2020-05-18 2025-06-20 诺华股份有限公司 Lnp023的结晶形式
JP7293513B2 (ja) 2020-07-16 2023-06-19 ノバルティス アーゲー Ｂ因子阻害剤の使用方法
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors
CN114057692B (zh) * 2020-08-07 2023-07-21 上海美悦生物科技发展有限公司 一种杂环类化合物、其制备方法及用途
KR20230049115A (ko) * 2020-08-07 2023-04-12 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도
CA3193488A1 (en) 2020-09-23 2022-03-31 Jason Allan Wiles Pharmaceutical compounds for the treatment of complement mediated disorders
CN116438170B (zh) * 2020-12-30 2024-12-13 江苏恒瑞医药股份有限公司 含氮桥杂环化合物、其制备方法及其在医药上的应用
US20240109861A1 (en) * 2020-12-30 2024-04-04 Medshine Discovery Inc. Series of piperidine-substituted benzoic acid compounds, and use thereof
EP4277982A1 (en) * 2021-01-14 2023-11-22 Alexion Pharmaceuticals, Inc. Macrocycle complement factor b inhibitors
CN117062810A (zh) * 2021-04-16 2023-11-14 正大天晴药业集团股份有限公司 一系列双环取代的芳香羧酸类化合物
WO2022234541A1 (en) 2021-05-07 2022-11-10 Novartis Ag Iptacopan for the treatment of atypical hemolytic uremic syndrome
PE20250114A1 (es) * 2021-06-03 2025-01-16 Chinook Therapeutics Inc Compuestos indol sustituidos y metodos de uso de los mismos
US20240277689A1 (en) 2021-06-18 2024-08-22 Novartis Ag Method of treating an autoimmune hematological disorder
WO2023278698A1 (en) * 2021-06-30 2023-01-05 Apellis Pharmaceuticals, Inc. Complement inhibition
CN118043314A (zh) 2021-08-18 2024-05-14 西藏海思科制药有限公司 一种苯并氮杂芳环衍生物及其在医药上的应用
JP2024530344A (ja) * 2021-09-07 2024-08-16 ノバルティス アーゲー 加齢黄斑変性の処置のためのｂ因子阻害剤の使用
AU2022376760A1 (en) * 2021-10-27 2024-05-02 Hansoh Bio Llc Piperidinyl indole derivatives, preparation methods and medicinal uses thereof
PE20242005A1 (es) 2022-01-24 2024-10-03 Novartis Ag Derivados espirociclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos
EP4471021A4 (en) * 2022-01-26 2025-04-30 Shanghai Meiyue Biotech Development Co., Ltd. Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
WO2023166487A1 (en) 2022-03-04 2023-09-07 Novartis Ag Use of iptacopan for the treatment of lupus nephritis
WO2023187715A1 (en) 2022-04-01 2023-10-05 Novartis Ag Complement factor b inhibitors and uses thereof
CN119698414A (zh) * 2022-06-20 2025-03-25 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
CN119546585A (zh) * 2022-06-23 2025-02-28 上海济煜医药科技有限公司 吲哚化合物的制备、应用及用途
CN117327070A (zh) * 2022-06-30 2024-01-02 江苏恒瑞医药股份有限公司 一种含氮桥杂环衍生物的晶型及其制备方法
KR20250027806A (ko) * 2022-06-30 2025-02-27 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질소 함유 브릿지 헤테로시클릭 유도체의 약학적으로 허용 가능한 염, 결정형 및 이의 제조 방법
WO2024046277A1 (zh) * 2022-08-29 2024-03-07 南京明德新药研发有限公司 一系列含氮桥杂环化合物及其制备方法
TW202423426A (zh) * 2022-08-31 2024-06-16 美商奇努克醫療股份有限公司 經取代之吲哚化合物及其使用方法
JP2025530222A (ja) 2022-09-10 2025-09-11 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ２－置換ピペリジン誘導体、その製造方法及び医薬的用途
CN118026998A (zh) 2022-11-11 2024-05-14 上海医药工业研究院有限公司 哌啶取代的苯甲酸类化合物、其药物组合物和应用
US20260159497A1 (en) * 2022-11-14 2026-06-11 Novartis Pharma Ag Solid forms of a complement factor b inhibitor
CN120303261A (zh) * 2022-11-29 2025-07-11 上海济煜医药科技有限公司 苯并螺环吲哚化合物的制备、应用及用途
WO2024141011A1 (zh) * 2022-12-31 2024-07-04 深圳晶泰科技有限公司 补体因子b抑制剂及其药物组合物和应用
WO2024148274A1 (en) * 2023-01-05 2024-07-11 Apellis Pharmaceuticals, Inc. Complement inhibition
TW202434240A (zh) 2023-02-22 2024-09-01 大陸商西藏海思科製藥有限公司 苯並氮雜芳環衍生物的藥物組合物及其在醫藥上的應用
AU2024226444A1 (en) 2023-02-23 2025-07-24 Novartis Ag Methods of using factor b inhibitors
CN118684668A (zh) * 2023-03-21 2024-09-24 上海美悦生物科技发展有限公司 螺环类化合物及其药物组合物、制备方法和用途
AU2024261191A1 (en) 2023-04-27 2025-11-06 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Salt of piperidylindole compound and preparation method therefor
CN121752557A (zh) 2023-07-04 2026-03-27 希塔拉生物有限公司 2-(1h-吲哚-4-基)甲基)-异吲哚啉衍生物作为因子b抑制剂
EP4739390A1 (en) 2023-07-04 2026-05-13 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors
WO2025008516A2 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Novel compounds
WO2025008517A1 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Indole derivatives with factor b inhibitory activity
CN119371402A (zh) 2023-07-26 2025-01-28 上海美悦生物科技发展有限公司 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途
TW202508580A (zh) 2023-08-25 2025-03-01 瑞士商諾華公司 使用因子b抑制劑之方法
TW202515541A (zh) 2023-09-29 2025-04-16 瑞士商諾華公司 補體因子ｂ抑制劑及其用途
WO2025083621A1 (en) 2023-10-20 2025-04-24 Novartis Ag Treatment of hidradenitis suppurativa using anti-baff-r antibodies
CN122396492A (zh) * 2023-12-05 2026-07-14 西藏海思科制药有限公司 苯并氮杂芳环衍生物在治疗补体因子b介导的疾病中的用途
TW202532059A (zh) 2023-12-29 2025-08-16 大陸商江蘇恆瑞醫藥股份有限公司 一種含氮橋雜環化合物的晶體及其製備方法
AU2024417894A1 (en) * 2024-01-10 2026-07-30 Hebei Yiling Medicine Research Institute Co. Ltd. Piperidinyl indole derivative, preparation method therefor and use thereof
WO2025172535A1 (en) 2024-02-15 2025-08-21 Sitala Bio Ltd Indole and benzimidazole compounds as factor b inhibitors
WO2025172910A1 (en) 2024-02-16 2025-08-21 Novartis Ag Factor b inhibitors for treatment of anca-associated vasculitis
TW202600134A (zh) * 2024-03-08 2026-01-01 大陸商江蘇豪森藥業集團有限公司 一種多元螺環化合物的鹽及其晶型、其製備方法和醫藥用途
TW202611049A (zh) * 2024-05-11 2026-03-16 香港商禮邦醫藥（香港）有限公司 補體因子b抑制劑
WO2025252133A1 (zh) * 2024-06-07 2025-12-11 润尔眼科药物（广州）有限公司 一种含吲哚基团的化合物及其用途
WO2025256647A1 (zh) * 2024-06-14 2025-12-18 润尔眼科药物（广州）有限公司 化合物及其医药用途
WO2026002007A1 (zh) * 2024-06-25 2026-01-02 珠海联邦制药股份有限公司 补体因子b抑制剂及其药物组合物和应用
WO2026003809A1 (en) 2024-06-29 2026-01-02 Assia Chemical Industries Ltd. Solid state forms of iptacopan hydrochloride
WO2026008074A1 (zh) * 2024-07-05 2026-01-08 南京正大天晴制药有限公司 补体因子b抑制剂的晶型、其制备方法及用途
WO2026042088A1 (en) * 2024-08-21 2026-02-26 Zydus Lifesciences Limited Trycyclic derivatives and their use as complement factor b inhibitors
WO2026069246A1 (en) 2024-09-30 2026-04-02 Novartis Ag Complement factor b inhibitors and uses thereof
WO2026086939A1 (zh) * 2024-10-25 2026-04-30 上海美悦生物科技发展有限公司 杂环化合物在制备预防或治疗IgA肾病的药物中的用途
WO2026093943A1 (en) 2024-10-31 2026-05-07 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives
GB202500206D0 (en) 2025-01-08 2025-02-19 Sitala Bio Ltd Novel compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093101A1 (en) * 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
WO2013164802A1 (en) * 2012-05-04 2013-11-07 Novartis Ag Complement pathway modulators and uses thereof
WO2013192345A1 (en) * 2012-06-20 2013-12-27 Novartis Ag Complement pathway modulators and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030357A1 (es) 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10237723A1 (de) * 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
AU2003286321A1 (en) 2002-12-19 2004-07-14 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
WO2004099170A2 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
EP1836182A2 (en) 2004-11-18 2007-09-26 The Institutes for Pharmaceutical Discovery, LLC Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
EP1851203A2 (en) 2005-02-08 2007-11-07 Merck & Co., Inc. Inhibitors of checkpoint kinases
EP2205085A1 (en) 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
US20100331298A1 (en) 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
WO2011006794A1 (en) 2009-07-14 2011-01-20 Nerviano Medical Sciences S.R.L. 3-oxo-2, 3-dihydro-lh-isoindole-4-carboxamides as parp inhibitors
CA2791738C (en) 2010-03-01 2020-06-09 Gtx, Inc. Aryl imidazolyl compounds for the treatment of cancer
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093101A1 (en) * 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
WO2013164802A1 (en) * 2012-05-04 2013-11-07 Novartis Ag Complement pathway modulators and uses thereof
WO2013192345A1 (en) * 2012-06-20 2013-12-27 Novartis Ag Complement pathway modulators and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2818684C1 (ru) * 2020-05-18 2024-05-03 Новартис Аг Кристаллическая форма lnp023
RU2853104C1 (ru) * 2020-12-30 2025-12-18 Цзянсу Хэнжуй Фармасьютикалз Ко., Лтд. Азотсодержащее мостиковое гетероциклическое соединение, способ его получения и его применение в медицине

Also Published As

Publication number Publication date
NL301292I2 (nl) 2024-10-30
EP3022192B1 (en) 2017-10-11
CN105579444B (zh) 2018-05-01
PL3022192T3 (pl) 2018-03-30
LT3022192T (lt) 2017-12-27
CY2024027I2 (el) 2025-09-26
CY1119767T1 (el) 2018-06-27
CU24397B1 (es) 2019-04-04
CL2016000060A1 (es) 2016-06-10
JP6378761B2 (ja) 2018-08-22
GT201600007A (es) 2018-12-18
US20180009795A1 (en) 2018-01-11
IL268623A (en) 2019-10-31
CA2917839C (en) 2022-05-03
PH12016500072B1 (en) 2016-04-18
SV2016005137A (es) 2018-06-12
AU2014290298A1 (en) 2016-02-11
TWI641600B (zh) 2018-11-21
NO2024042I1 (no) 2024-09-30
HUE037510T2 (hu) 2018-09-28
IL243540B (en) 2019-09-26
FR24C1036I1 (fr) 2024-12-06
FIC20240032I1 (fi) 2024-10-01
US10093663B2 (en) 2018-10-09
KR102242742B1 (ko) 2021-04-23
LUC00358I1 (enExample) 2024-09-30
TN2016000017A1 (en) 2017-07-05
HK1221217A1 (en) 2017-05-26
JO3425B1 (ar) 2019-10-20
HRP20172000T1 (hr) 2018-02-09
CA2917839A1 (en) 2015-01-22
BR112016000909A2 (pt) 2017-07-25
UY35663A (es) 2015-02-27
US20160152605A1 (en) 2016-06-02
SI3022192T1 (en) 2018-01-31
RS56721B1 (sr) 2018-03-30
EA201690223A1 (ru) 2016-06-30
EP3022192A1 (en) 2016-05-25
TW201546058A (zh) 2015-12-16
ES2655855T3 (es) 2018-02-21
NZ715780A (en) 2021-03-26
KR20160030556A (ko) 2016-03-18
MY196427A (en) 2023-04-10
FR24C1036I2 (fr) 2025-08-01
UA117371C2 (uk) 2018-07-25
CN105579444A (zh) 2016-05-11
MX351291B (es) 2017-10-09
PH12016500072A1 (en) 2016-04-18
MY187454A (en) 2021-09-22
AU2014290298B2 (en) 2017-06-15
SG11201600086PA (en) 2016-02-26
LUC00358I2 (enExample) 2026-05-05
CU20160006A7 (es) 2016-08-31
IL243540A0 (en) 2016-02-29
WO2015009616A1 (en) 2015-01-22
PT3022192T (pt) 2018-01-15
IL268623B (en) 2020-01-30
HUS2400034I1 (hu) 2024-10-28
AP2016008992A0 (en) 2016-01-31
JP2016526576A (ja) 2016-09-05
BR112016000909B1 (pt) 2023-05-02
DK3022192T3 (en) 2018-01-22
ES2655855T4 (es) 2024-09-06
LTPA2024526I1 (enExample) 2024-10-10
CY2024027I1 (el) 2025-09-26
EP3299365A1 (en) 2018-03-28
US9682968B2 (en) 2017-06-20
BR112016000909A8 (pt) 2020-01-07
PE20161066A1 (es) 2016-10-30

Similar Documents

Publication Publication Date Title
PE20241127A1 (es) Compuestos triciclicos como inhibidores de kras
JP2021038263A (ja) 治療上活性な化合物およびそれらの使用方法
JP2016526576A5 (enExample)
JPWO2020085493A5 (enExample)
SI2961736T1 (en) Histone demethylase inhibitors
RU2017124136A (ru) Трициклическое спиро-соединение
SI3022192T1 (en) Piperidinyl indole derivatives and their use as inhibitors of complementary factor B
RU2505534C2 (ru) Производные хиназолина, ингибирующие активность egfr
KR20190092538A (ko) C-kit 억제제로서의 벤즈이미다졸 화합물
KR20120062839A (ko) 단백질 키나제 억제제로서의 화합물 및 조성물
RU2014147193A (ru) Новые конденсированные пиримидиновые производные для ингибирования тирозинкиназной активности
RU2014105624A (ru) Соединения индазола, способ их применения и фармацевтическая композиция
RU2010126105A (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства
JP2014505660A5 (enExample)
JP2012522053A5 (enExample)
JP2008508214A (ja) 女性の性障害の治療用ピペラジン誘導体
JP2019519520A (ja) ヒストンデメチラーゼ阻害剤としてのイミダゾール
KR20160054547A (ko) 비스테로이드성 항염증 약물 및 시그마 리셉터 리간드 조합들
US9745282B2 (en) Indoline compounds as aldosterone synthase inhibitors
JP2022554392A5 (enExample)
JP2017500321A5 (enExample)
RU2013136861A (ru) Новое производное индола или индазола или его соль
RU2013120338A (ru) Производное 1,2,4-триазолана
JP2015500267A5 (enExample)
JP5859115B2 (ja) １，４−ジヒドロピリジン−３，５−ジカルボキシラート誘導体、その調製方法及びその使用

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM